Pan-JAK inhibitors (topical delgocitinib [65] and oral gusacitinib [66]) and JAK1-inhibitors (oral baricitinib [67] and upadacitinib [68]) demonstrated promising efficacy in chronic HE in recent RCTs or case-reports. Here, JAK1 is linked to hereditary elliptocytosis.